drugset
drugset / Trial / NCT04608500

A Study (Study 2) to Evaluate the Safety and Efficacy of FMX103 1.5% Topical Minocycline Foam in the Treatment of Facial Papulopustular Rosacea

NCT04608500 ↗

Phase 3 Completed 771 enrolled Vyne Therapeutics Inc. Premier Research · collab
RandomizedParallel-groupDouble-blindTreatment

Summary

The primary objectives of this study are to determine the efficacy and safety of FMX103 1.5% minocycline foam applied topically once daily for 12 weeks in the treatment of rosacea.

Timeline

Start
2017-06-01
Primary completion
2018-07-02
Completion
2018-07-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Minocycline Small molecule 1.5 % Topical
Subject Minocycline Small molecule 7.5 mg Topical

Indications

rosacea